Literature DB >> 19165556

Is the Alifax Test-1TH useful to determine the Disease Activity Score (DAS28) in rheumatoid arthritis patients?

M Levitus1, A Pelliccia, R J van de Stadt, A E Voskuyl, A A Bouman.   

Abstract

Treatment of rheumatoid arthritis (RA) is monitored with the disease activity score (DAS28), for which the erythrocyte sedimentation rate (ESR) is needed. Apart from the original gold standard method, other methods like the Alifax Test-1TH apparatus are widely used in laboratory worldwide. We compared ESR values obtained by the Alifax Test-1Th apparatus and the gold standard method for 218 RA patients. We found a good correlation (r=0.87) between the Alifax Test-1TH results and the gold standard method. A good correlation (r=0.96) was also found for the DAS28 results obtained with both methods. The number of patients that were misclassified when the Alifax Test-1TH is used is reasonable for both the ESR (14.7%) and the DAS28 (10.6%). These results suggest that it may be useful to determine the ESR by the Alifax Test-1TH, with a DAS28 misclassification in less than 11% of the patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165556     DOI: 10.1007/s10067-009-1092-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Erythrocyte sedimentation rate: use of fresh blood for quality control.

Authors:  Mario Plebani; Elisa Piva
Journal:  Am J Clin Pathol       Date:  2002-04       Impact factor: 2.493

2.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Authors:  D M van der Heijde; M A van 't Hof; P L van Riel; L A Theunisse; E W Lubberts; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

3.  Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).

Authors:  J Ledingham; C Deighton
Journal:  Rheumatology (Oxford)       Date:  2005-01-05       Impact factor: 7.580

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

Review 5.  Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care.

Authors:  T Pincus; T Sokka
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

6.  A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I.

Authors:  H Passing
Journal:  J Clin Chem Clin Biochem       Date:  1983-11

Review 7.  DAS remission cut points.

Authors:  J Fransen; P L C M van Riel
Journal:  Clin Exp Rheumatol       Date:  2006 Nov-Dec       Impact factor: 4.473

8.  Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score.

Authors:  M L Prevoo; A M van Gestel; M A van T Hof; M H van Rijswijk; L B van de Putte; P L van Riel
Journal:  Br J Rheumatol       Date:  1996-11

9.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

10.  Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.

Authors:  J Fransen; M C W Creemers; P L C M Van Riel
Journal:  Rheumatology (Oxford)       Date:  2004-07-06       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.